PIC/S revises Annex 14 for Medicinal Products derived from Human Blood or Plasma
![Bioburden - Live Online Training](files/eca/userImages/training.img/Z-ECA-Bioburden-LOT.jpg)
Recommendation
15/16 October 2024
Regulatory Expectations and Practical Experiences
On 31 January, the PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME (PIC/S) published the revised Annex 14 of the PIC/S GMP Guide (PE 009-11). This Annex will apply to medicinal products derived from human blood or plasma, fractionated in or imported into the country as well as to starting materials for these products. The document provides specific guidance on GMP practices related to the collection, processing, storage and transport.
Furthermore the Annex can also be used for stable derivatives of human blood or human plasma (e.g. Albumin) incorporated into medical devices. In this case, it should be used in line with the national legislation. Additionally, the Annex 14 addresses specific provisions for when starting material is imported from other countries and for contract fractionation programs for other countries.
The revised document includes the following parts:
- Glossary
- Scope
- Principles
- Quality Management
- Traceability and Post Collection Measures
- Premises and equipment
- Manufacturing
- Quality Control
- Release of intermediate and finished products
- Retention of plasma pool samples
- Disposal of waste
For the complete document please look at the PIC/S GMP Guide (PE 009-11).
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs